{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Focal+Segmental+Glomerulosclerosis+%28FSGS%29",
    "query": {
      "condition": "Primary Focal Segmental Glomerulosclerosis (FSGS)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Focal+Segmental+Glomerulosclerosis+%28FSGS%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T20:50:13.018Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02633046",
      "title": "Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Idiopathic Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Acthar Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt ARD LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2016-10-10",
      "completion_date": "2020-08-27",
      "has_results": true,
      "last_update_posted_date": "2021-08-04",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Chula Vista, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633046"
    },
    {
      "nct_id": "NCT04065438",
      "title": "Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "LIPOSORBER® LA-15",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Kaneka Medical America LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 35,
      "start_date": "2020-01-01",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 10,
      "location_summary": "Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04065438"
    },
    {
      "nct_id": "NCT02921789",
      "title": "Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation",
        "Primary Focal Segmental Glomerulosclerosis (FSGS)"
      ],
      "interventions": [
        {
          "name": "Bleselumab",
          "type": "DRUG"
        },
        {
          "name": "Basiliximab",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus Capsules",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2017-05-22",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02921789"
    },
    {
      "nct_id": "NCT00550342",
      "title": "Rituximab Treatment of Focal Segmental Glomerulosclerosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis (FSGS)"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "5 Years to 60 Years"
      },
      "enrollment_count": 0,
      "start_date": "2008-01",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00550342"
    },
    {
      "nct_id": "NCT00816504",
      "title": "Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Galactose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "2 Years to 60 Years"
      },
      "enrollment_count": 0,
      "start_date": "2008-12",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2015-09-07",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00816504"
    },
    {
      "nct_id": "NCT06500702",
      "title": "A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis",
        "Glomerulonephritis Minimal Lesion"
      ],
      "interventions": [
        {
          "name": "frexalimab",
          "type": "DRUG"
        },
        {
          "name": "brivekimig",
          "type": "DRUG"
        },
        {
          "name": "rilzabrutinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 84,
      "start_date": "2024-12-19",
      "completion_date": "2028-02-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06500702"
    },
    {
      "nct_id": "NCT00193648",
      "title": "Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Focal Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone (Avandia)",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab (Humira)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 21,
      "start_date": "2005-07",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2007-10-22",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 2,
      "location_summary": "New Hyde Park, New York • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00193648"
    },
    {
      "nct_id": "NCT04983888",
      "title": "Obinutuzumab in Primary FSGS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-11-17",
      "completion_date": "2025-06-16",
      "has_results": true,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04983888"
    },
    {
      "nct_id": "NCT06466135",
      "title": "Study of WAL0921 in Patients With Glomerular Kidney Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Nephropathies",
        "Primary Focal Segmental Glomerulosclerosis",
        "Minimal Change Disease",
        "Primary Immunoglobulin A Nephropathy",
        "Primary Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "WAL0921",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walden Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 96,
      "start_date": "2024-07-02",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hinsdale",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06466135"
    },
    {
      "nct_id": "NCT03703908",
      "title": "A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "CCX140-B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-10-01",
      "completion_date": "2020-06-24",
      "has_results": true,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-10-02T20:50:13.018Z",
      "location_count": 5,
      "location_summary": "Torrance, California • Shreveport, Louisiana • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03703908"
    }
  ]
}